Pulled From EU Assessment Process: Orphan Drugs For Kidney Disease, Mesothelioma
Two orphan medicines have been withdrawn from the evaluation process at the European Medicines Agency, one of them for recurrent nephrotic syndrome, the other for mesothelioma. Three products are undergoing a re-evaluation after an initial negative opinion from the CHMP.
You may also be interested in...
Fourteen medicines that are in the final stages of the evaluation process at the European Medicines Agency should find out this week whether they will be approved for marketing across the EU.
The European Medicines Agency’s key scientific committee, the CHMP, is deciding this week whether a dozen or so new medicines that are in the final stages of the evaluation process should be approved for marketing across the EU. The committee will discuss 13 initial marketing authorization applications.
The European Medicines Agency's advisory committee, the CHMP, unusually issued three negative opinions at its recent monthly meeting. Which companies received an unexpected boon at the news?